| First Author | Hill JD | Year | 2019 |
| Journal | Brain Behav Immun | Volume | 76 |
| Pages | 165-181 | PubMed ID | 30465881 |
| Mgi Jnum | J:309803 | Mgi Id | MGI:6709390 |
| Doi | 10.1016/j.bbi.2018.11.017 | Citation | Hill JD, et al. (2019) Activation of GPR55 induces neuroprotection of hippocampal neurogenesis and immune responses of neural stem cells following chronic, systemic inflammation. Brain Behav Immun 76:165-181 |
| abstractText | New neurons are continuously produced by neural stem cells (NSCs) within the adult hippocampus. Numerous diseases, including major depressive disorder and HIV-1 associated neurocognitive disorder, are associated with decreased rates of adult neurogenesis. A hallmark of these conditions is a chronic release of neuroinflammatory mediators by activated resident glia. Recent studies have shown a neuroprotective role on NSCs of cannabinoid receptor activation. Yet, little is known about the effects of GPR55, a candidate cannabinoid receptor, activation on reductions of neurogenesis in response to inflammatory insult. In the present study, we examined NSCs exposed to IL-1beta in vitro to assess inflammation-caused effects on NSC differentiation and the ability of GPR55 agonists to attenuate NSC injury. NSC differentiation and neurogenesis was determined via immunofluorescence and flow cytometric analysis of NSC markers (Nestin, Sox2, DCX, S100beta, betaIII Tubulin, GFAP). GPR55 agonist treatment protected against IL-1beta induced reductions in neurogenesis rates. Moreover, inflammatory cytokine receptor mRNA expression was down regulated by GPR55 activation in a neuroprotective manner. To determine inflammatory responses in vivo, we treated C57BL/6 and GPR55(-/-) mice with LPS (0.2mg/kg/day) continuously for 14days via osmotic mini-pump. Reductions in NSC survival (as determined by BrdU incorporation), immature neurons, and neuroblast formation due to LPS were attenuated by concurrent direct intrahippocampal administration of the GPR55 agonist, O-1602 (4microg/kg/day). Molecular analysis of the hippocampal region showed a suppressed ability to regulate immune responses by GPR55(-/-) animals manifesting in a prolonged inflammatory response (IL-1beta, IL-6, TNFalpha) after chronic, systemic inflammation as compared to C57BL/6 animals. Taken together, these results suggest a neuroprotective role of GPR55 activation on NSCs in vitro and in vivo and that GPR55 provides a novel therapeutic target against negative regulation of hippocampal neurogenesis by inflammatory insult. |
